Operator
Good morning, and welcome to the Plexus Corp Conference Call regarding its Fiscal Second Quarter 2021 Earnings Announcement. My name is Tiffany, and I will be your operator for today s call. [Operator Instructions] After a brief discussion by management, we will open the conference call for questions. [Operator Instructions] I would now like to turn the call over to Mr. Shawn Harrison, Plexus Vice President of Communication and Investor Relations. Shawn?
Shawn Harrison
Vice President, Communications & Investor Relations
Thank you, Tiffany. Good morning, and thank you for joining us today. Some of the statements made and information provided during our call today will be forward-looking statements as they will not be limited to historical facts. The words believe, expect, intend, plan, anticipate, and similar terms often identify forward-looking statements. Forward-looking statements are not guarantees since there are inherent difficulties in predicting future results
Plexus Corp (PLXS) Q2 2021 Earnings Call Transcript msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Company’s Confidence in MRTP Authorization is High; Launch of VLN® is Only the Beginning for Tobacco Franchise 22nd Century Group, Inc. (NYSE American: XXII), a
PJSC Polyus Moody s upgrades PJSC Polyus ratings to Baa3 with a stable outlook PJSC Polyus (LSE, MOEX - PLZL) ( Polyus , or the Company ) notes that Moody s Investors Service ( Moody s ) has upgraded the Company s Rating to Baa3 /stable from Ba1 /stable. In assigning Polyus a Baa3 Rating, Moody s highlighted the Company s track record of deleveraging supported by strong cash flow generation on the back of its solid operating performance and pro-active debt management. The upgrade also reflects the Company s global cost leadership, stellar reserve base and its history of organic growth, with Sukhoi Log further contributing to strengthening of the Company s business profile. Among other rating drivers, Moody s underscored the Company s conservative financial policy amid various gold price scenarios and continuous efforts on ESG front.
Share:
MONT-SAINT-GUIBERT, Belgium, April 19, 2021 (GLOBE NEWSWIRE) Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced the appointment of Dr. Charles Morris to the position of Chief Medical Officer. Dr. Morris will lead and provide strategic direction for all medical, regulatory and clinical development activities. We are delighted to bring someone with Dr. Morris s vast expertise and experience on board during this pivotal time in the Company, said Filippo Petti, CEO of Celyad Oncology. Dr. Morris has played an integral part in guiding multiple late-stage oncology drugs to approval and his demonstrated track record of leadership in the pharmaceutical industry will greatly benefit the work we are doing at Celyad Oncology.